Wave Life Sciences Ltd. - Ordinary Shares (WVE): Price and Financial Metrics
GET POWR RATINGS... FREE!
WVE POWR Grades
- WVE scores best on the Growth dimension, with a Growth rank ahead of 55.84% of US stocks.
- The strongest trend for WVE is in Momentum, which has been heading down over the past 31 weeks.
- WVE ranks lowest in Momentum; there it ranks in the 5th percentile.
WVE Stock Summary
- Of note is the ratio of Wave Life Sciences Ltd's sales and general administrative expense to its total operating expenses; just 11.86% of US stocks have a lower such ratio.
- With a price/sales ratio of 21.21, Wave Life Sciences Ltd has a higher such ratio than 90.62% of stocks in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for WVE comes in at -48.16% -- higher than that of only 5.12% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Wave Life Sciences Ltd, a group of peers worth examining would be CTMX, PIRS, MRUS, DTIL, and MCRB.
- WVE's SEC filings can be seen here. And to visit Wave Life Sciences Ltd's official web site, go to www.wavelifesciences.com.
WVE Stock Price Chart Interactive Chart >
WVE Price/Volume Stats
|Current price||$7.24||52-week high||$19.98|
|Prev. close||$7.47||52-week low||$4.82|
|Day high||$7.55||Avg. volume||828,762|
|50-day MA||$6.41||Dividend yield||N/A|
|200-day MA||$8.83||Market Cap||360.96M|
Wave Life Sciences Ltd. - Ordinary Shares (WVE) Company Bio
WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company was founded in 2012 and is based in Simgapore.
WVE Latest News Stream
|Loading, please wait...|
WVE Latest Social Stream
View Full WVE Social Stream
Latest WVE News From Around the Web
Below are the latest news stories about Wave Life Sciences Ltd that investors may wish to consider to help them evaluate WVE as an investment opportunity.
Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study
Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin deficiency (AATD). AATD is a genetic disorder that may result in lung disease or liver disease. Up to 40% editing of human SERPINA1 Z-allele mRNA in the liver was observed at a single time point, which resulted in a therapeutically meaningful increase in circulating functional wild-type AAT protein. Ed
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating functional AAT protein Wave’s program in alpha-1 antitrypsin deficiency aims to correct the single base mutation in mRNA derived from the SERPINA1 Z allele, thereby addressing both lung and liver manifestations of the disease CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Na
The following slide deck was published by Wave Life Sciences Ltd. in conjunction with this event....
The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2021 Q1 earnings call....
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -53.57% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
WVE Price Returns